Skip to Main Content

Advertisement

Why Submit to Blood



  • In continuous publication since 1946, Blood is THE #1 cited journal in the field of hematology.
  • With an average of 443 references daily, Blood is the best vehicle for reaching the hematology realm.
  • Blood editors are experts within the field of hematology and manuscripts are reviewed by prominent specialists.


"I publish in Blood because of the impact the journal has on influencing practice and subsequent research, and because I know the findings from my research will be disseminated quickly."

Mikkael Sekeres MD, MS, Professor of Medicine, Cleveland Clinic
 

How to Get Published in a Peer-Reviewed Journal: Presentation

Bob Löwenberg, MD, PhD
Blood Editor-in-Chief
Erasmus University Medical Center
Rotterdam, the Netherlands 

Author Voices:

Brad Kahl, MD

Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., … Wagner-Johnston, N. D. (2014). A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/ refractory mantle cell lymphoma (MCL).
Blood, 123(22), 3398–3405. 


Author Resources   
Submit to Blood 
Author Guide 
Journal Scope 
Style Guide
Author's FAQs 
Article Collections 
      




Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement

X